HC Wainwright & Co. Reiterates Buy on Jasper Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating for Jasper Therapeutics (NASDAQ:JSPR) and maintained a price target of $65.
October 15, 2024 | 9:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Jasper Therapeutics, maintaining a $65 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $65 price target by a reputable analyst firm like HC Wainwright & Co. suggests positive sentiment and confidence in Jasper Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100